T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Apple
AAPL
|
+$4.53B |
| 2 |
Broadcom
AVGO
|
+$1.7B |
| 3 |
GE Vernova
GEV
|
+$1.29B |
| 4 |
International Paper
IP
|
+$1.11B |
| 5 |
Tesla
TSLA
|
+$956M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.44B |
| 2 |
NVIDIA
NVDA
|
+$2.09B |
| 3 |
Constellation Energy
CEG
|
+$1.9B |
| 4 |
Qualcomm
QCOM
|
+$1.84B |
| 5 |
Amazon
AMZN
|
+$1.56B |
Sector Composition
| 1 | Technology | 34% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Communication Services | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1026
C.H. Robinson
CHRW
$15.8B
| $14.8M | ﹤0.01% |
167,595
+6,281
| +4% | +$554K |
|
1027
Lennox International
LII
$19.4B
| $14.7M | ﹤0.01% |
27,424
+9,950
| +57% | +$5.32M |
|
|
NARI
1028
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $14.6M | ﹤0.01% |
304,033
-69,314
| -19% | -$3.34M |
|
1029
Centrus Energy
LEU
$4.24B
| $14.5M | ﹤0.01% |
340,038
+1,788
| +0.5% | +$76.4K |
|
1030
Cars.com
CARS
$828M
| $14.3M | ﹤0.01% |
727,988
+683,975
| +1,554% | +$13.5M |
|
1031
Kyndryl
KD
$7.3B
| $14.1M | ﹤0.01% |
536,967
+407,264
| +314% | +$10.7M |
|
1032
F5
FFIV
$18.6B
| $14.1M | ﹤0.01% |
81,906
+1,614
| +2% | +$278K |
|
1033
Doximity
DOCS
$13.5B
| $14.1M | ﹤0.01% |
503,744
-56,082
| -10% | -$1.57M |
|
1034
SLM Corp
SLM
$5.83B
| $14M | ﹤0.01% |
674,107
-142,167
| -17% | -$2.96M |
|
1035
Owens Corning
OC
$12.6B
| $13.9M | ﹤0.01% |
80,259
+5,789
| +8% | +$1.01M |
|
1036
Maplebear
CART
$12.1B
| $13.8M | ﹤0.01% |
430,773
-3,522,843
| -89% | -$113M |
|
1037
Enpro
NPO
$4.54B
| $13.8M | ﹤0.01% |
95,093
+79,687
| +517% | +$11.6M |
|
1038
Evolent Health
EVH
$1.02B
| $13.8M | ﹤0.01% |
722,959
+5,625
| +0.8% | +$108K |
|
1039
Invesco Senior Loan ETF
BKLN
$6.8B
| $13.8M | ﹤0.01% |
656,100
| – | – |
|
1040
Selective Insurance
SIGI
$4.69B
| $13.8M | ﹤0.01% |
147,063
-299,496
| -67% | -$28.1M |
|
1041
Amicus Therapeutics
FOLD
$2.48B
| $13.8M | ﹤0.01% |
1,390,047
+686
| +0% | +$6.81K |
|
1042
iShares Core MSCI EAFE ETF
IEFA
$155B
| $13.8M | ﹤0.01% |
189,741
-69,926
| -27% | -$5.08M |
|
|
VRNA
1043
Verona Pharma
VRNA
$9.2B
| $13.7M | ﹤0.01% |
+949,375
| New | +$13.7M |
|
1044
Corbus Pharmaceuticals
CRBP
$129M
| $13.7M | ﹤0.01% |
302,186
+109,691
| +57% | +$4.96M |
|
1045
Incyte
INCY
$16.3B
| $13.6M | ﹤0.01% |
225,112
-418,544
| -65% | -$25.4M |
|
1046
First Citizens BancShares
FCNCA
$23.9B
| $13.6M | ﹤0.01% |
8,085
-684
| -8% | -$1.15M |
|
1047
Allogene Therapeutics
ALLO
$264M
| $13.5M | ﹤0.01% |
5,790,542
+1,612,923
| +39% | +$3.76M |
|
1048
Essent Group
ESNT
$6.16B
| $13.3M | ﹤0.01% |
237,440
+60,313
| +34% | +$3.39M |
|
1049
Tapestry
TPR
$22.7B
| $13.3M | ﹤0.01% |
310,787
+6,013
| +2% | +$257K |
|
1050
Markel Group
MKL
$24.2B
| $13.2M | ﹤0.01% |
8,382
+46
| +0.6% | +$72.5K |
|